<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Paraneoplastic visual syndromes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Paraneoplastic visual syndromes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Paraneoplastic visual syndromes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Josep Dalmau, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Myrna R Rosenfeld, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Trobe, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 14, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2791602"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Paraneoplastic neurologic syndromes are a heterogeneous group of neurologic disorders associated with systemic cancer and caused by mechanisms other than metastases, metabolic and nutritional deficits, infections, coagulopathy, or side effects of cancer treatment. In most cases, their pathogenesis is believed to be immune mediated.</p><p>Paraneoplastic visual syndromes are rare; they include cancer-associated retinopathy (CAR), melanoma-associated retinopathy (MAR), paraneoplastic optic neuropathy (optic neuritis; PON), and bilateral diffuse uveal melanocytic proliferation (BDUMP).</p><p>This topic discusses paraneoplastic visual syndromes. An overview of paraneoplastic syndromes and other paraneoplastic disorders are discussed separately. (See  <a class="medical medical_review" href="/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system"</a> and  <a class="medical medical_review" href="/d/html/5190.html" rel="external">"Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle"</a> and  <a class="medical medical_review" href="/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/15822.html" rel="external">"Paraneoplastic cerebellar degeneration"</a>.)</p><p class="headingAnchor" id="H2792544"><span class="h1">CANCER-ASSOCIATED RETINOPATHY</span><span class="headingEndMark"> — </span>Cancer-associated retinopathy (CAR), while rare, is probably the most common of the paraneoplastic visual syndromes.</p><p class="headingAnchor" id="H968322558"><span class="h2">Pathology and pathogenesis</span><span class="headingEndMark"> — </span>The pathogenesis of CAR is believed to be a B cell mediated autoimmune response directed against an antigen expressed by both tumor and retina [<a href="#rid1">1</a>]. T cell responses may also play a role.</p><p>Histopathology reveals diffuse loss of inner and outer segments of the photoreceptors and loss of the outer nuclear layer with preservation of the inner nuclear layer [<a href="#rid2">2</a>]. Inflammation is variably observed.</p><p class="headingAnchor" id="H343595128"><span class="h2">Clinical features</span></p><p class="headingAnchor" id="H2026280351"><span class="h3">Signs and symptoms</span><span class="headingEndMark"> — </span>Patients with CAR develop symptoms related to dysfunction of both cones (eg, photosensitivity, abnormal visual acuity, color vision abnormalities, central scotomata) and rods (eg, nyctalopia or night blindness, prolonged dark adaptation, peripheral or ring-like scotomata). Patients typically describe photopsias along with bilateral visual dimming that progress over days to weeks. Symptoms may initially be unilateral but progress to both eyes within weeks. The triad of photosensitivity, ring scotomatous visual field loss, and attenuated retinal arteriole caliber is strongly suggestive of this disorder, although the optic fundus can appear normal in the early stages [<a href="#rid3">3</a>]. Optic disc pallor and mottling of the epithelium develop in later stages [<a href="#rid4">4</a>].</p><p>The most commonly associated tumors are small cell lung cancer (SCLC), breast cancer, gynecologic cancers, and hematologic malignancies. Less frequently, hepatocellular carcinoma, colon cancer, prostate cancer, and thymoma have been reported [<a href="#rid4">4-10</a>]. CAR precedes the cancer diagnosis in approximately one-half of patients.</p><p class="headingAnchor" id="H3469610027"><span class="h3">Electroretinogram findings</span><span class="headingEndMark"> — </span>Electroretinogram (ERG) is abnormal, with depressed a and b waves in both photopic and scotopic conditions, reflecting damage to both rods and cones. ERG is useful in the evaluation because, if abnormal, it confirms that visual loss is due to a retinopathy. In addition, specific features of the ERG results can help distinguish between CAR and melanoma-associated retinopathy (MAR). (See <a class="local">'Melanoma-associated retinopathy'</a> below.)</p><p class="headingAnchor" id="H3596116465"><span class="h3">Antiretinal antibodies</span><span class="headingEndMark"> — </span>More than half of patients with CAR have serum autoantibodies that target retinal antigens. In one cohort of patients with paraneoplastic retinopathy, 65 percent were seropositive for antiretinal antibodies, including antibodies to alpha-enolase (30 percent), transducin-alpha (17 percent), carbonic anhydrase II (14 percent), and recoverin (10 percent) (<a class="graphic graphic_picture graphicRef67930" href="/d/graphic/67930.html" rel="external">picture 1</a>). Some of these antibodies associate with specific clinical features [<a href="#rid5">5</a>].</p><p>As these antibodies may be found in patients with systemic autoimmune disorders without visual symptoms as well as in patients with retinopathy without cancer, their presence supports an autoimmune process but does not confirm a paraneoplastic etiology. However, recoverin antibodies almost always associate with SCLC, and this helps to focus the cancer search [<a href="#rid11">11</a>]. Other antigens have been identified in patients with CAR; approximately 35 percent of patients with CAR are seronegative, suggesting that other antigens remain to be characterized [<a href="#rid5">5,12</a>].</p><p>Antirecoverin antibodies and anti-alpha-enolase antibodies have been shown to induce apoptotic death of photoreceptor cells in vitro, suggesting a direct or indirect role in the pathogenesis of the retinal degeneration [<a href="#rid13">13,14</a>].</p><p class="headingAnchor" id="H951751089"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>Patients with unexplained vision loss with clinical or ERG evidence of rod and cone dysfunction or known or suspected malignancy should be evaluated for CAR. Testing should include measurement of serum antiretinal antibodies along with investigation for underlying neoplasm. (See  <a class="medical medical_review" href="/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system", section on 'Search for occult malignancy'</a>.)</p><p>Negative serum antibody titers on initial examination can become positive on subsequent testing [<a href="#rid15">15</a>]. Cerebrospinal fluid (CSF) analysis is not routinely required in the evaluation of suspected CAR. CSF may be normal or show mild lymphocytic pleocytosis and/or elevated protein.</p><p class="headingAnchor" id="H692736090"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Traditionally, CAR has been treated with corticosteroids with anecdotal reports of mild to moderate improvement in visual function [<a href="#rid4">4,16</a>]. As with other paraneoplastic disorders, early institution of immunotherapy appears to improve the chance for treatment response [<a href="#rid17">17</a>]. Treatment of the underlying tumor does not clearly affect visual prognosis. (See  <a class="medical medical_review" href="/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system", section on 'Treatment and prognosis'</a>.)</p><p>There are anecdotal, uncontrolled reports of a treatment response to intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) [<a href="#rid18">18</a>], plasmapheresis [<a href="#rid19">19</a>], <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> [<a href="#rid9">9</a>], and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid20">20</a>]. In most patients, however, progressive visual loss and eventual blindness occur [<a href="#rid21">21</a>].</p><p>Patients treated with immune checkpoint inhibitors (ICI) have been reported as developing syndromes mimicking paraneoplastic retinopathy or optic neuropathy, including some with antiretinal antibodies [<a href="#rid22">22-24</a>]. Affected patients can have visual improvement after discontinuation of the ICI. At this time, there are no features known to distinguish symptoms due to adverse side effects of ICI from those caused by paraneoplastic mechanisms. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p class="headingAnchor" id="H2792551"><span class="h1">MELANOMA-ASSOCIATED RETINOPATHY</span><span class="headingEndMark"> — </span>Melanoma-associated retinopathy (MAR) usually presents in the setting of known melanoma, sometimes after an interval of months to years [<a href="#rid25">25</a>], although MAR may rarely precede the diagnosis of melanoma. Patients with any form of melanoma (cutaneous, choroidal, ciliary body, or choroidal nevi) may be affected, usually in the context of metastatic disease [<a href="#rid26">26,27</a>].</p><p class="headingAnchor" id="H3208283058"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Clinical features of MAR include shimmering, flickering, or pulsating photopsias, night blindness, and loss of peripheral vision [<a href="#rid25">25-28</a>]. Color vision is preserved. The onset is usually acute and may begin in one eye. In one series, visual acuity was 20/60 or better in more than 80 percent of patients at diagnosis [<a href="#rid25">25</a>]. Vision loss progresses slowly.</p><p>Ophthalmoscopic examination is usually normal at onset, with retinal arterial attenuation seen later [<a href="#rid2">2,25</a>]. Vitreous cells are seen in a few patients. The electroretinogram (ERG) shows a characteristic pattern of a markedly reduced b wave in the presence of a normal, dark-adapted a wave, consistent with bipolar and Muller cell dysfunction. Cerebrospinal fluid (CSF) analysis is generally normal.</p><p>The sera of patients with MAR often contain antibodies that react with the bipolar cells of the retina [<a href="#rid26">26,29,30</a>]. Antibodies to arrestin, transducin, rhodopsin, and transient receptor potential channel protein 1 (TRPM1) are some of many antibodies identified [<a href="#rid31">31-34</a>]. Intravitreal injection of patient TRPM1 antibodies in mice has resulted in attenuation of the ERG b wave and uptake of the human antibodies by the retinal ON-bipolar cells, suggesting a pathogenic role in the visual symptoms [<a href="#rid35">35</a>].</p><p>Antiretinal antibodies are also prevalent (in as much as 69 percent) in patients with melanoma but no retinopathy, as well as in healthy control subjects [<a href="#rid36">36,37</a>]. The target antigens have not been determined, and the clinical significance of these antibodies is unclear [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H4249666580"><span class="h2">Treatment and prognosis</span><span class="headingEndMark"> — </span>Vision loss typically stabilizes or progresses slowly. A minority of patients improve with treatment of the tumor and/or immunotherapy, including glucocorticoids, plasma exchange, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, or intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG; often at a dose of 0.4 g/kg daily for five days) [<a href="#rid4">4,5,21,25,38,39</a>]; there are no controlled studies.</p><p class="headingAnchor" id="H2791281"><span class="h1">OPTIC NEUROPATHY</span><span class="headingEndMark"> — </span>Paraneoplastic optic neuritis (PON) has been described in a few reports, usually in association with other paraneoplastic neurologic syndromes, in particular encephalomyelitis, retinitis, and sensorimotor neuropathy [<a href="#rid40">40-45</a>]. Many of these patients harbor antibodies to collapsin-responsive mediator protein 5 (CRMP5, also called anti-CV2) [<a href="#rid41">41-43,46</a>]. However, due to the small number of patients reported, the extensive number of accompanying symptoms, and the frequent co-occurrence of other antibodies, CRMP5 antibodies should not be considered as specific or sensitive markers of PON or cancer-associated retinitis [<a href="#rid42">42</a>].</p><p>Patients typically present with painless visual loss and optic disc edema [<a href="#rid2">2,42,45,47</a>]. Both eyes are usually ultimately involved. Magnetic resonance imaging (MRI) reveals a swollen optic nerve that may mildly enhance. <a class="drug drug_general" data-topicid="8461" href="/d/drug information/8461.html" rel="external">Fluorescein</a> angiography can show optic disc hyperfluorescence and leakage. Vitreous cells may be prominent. Cerebrospinal fluid (CSF) may reveal a mild lymphocytic pleocytosis and/or a mildly elevated protein. Neuropathologic findings include perivascular lymphocytic infiltration and demyelination of the optic nerve [<a href="#rid42">42,47</a>].</p><p>In addition to encephalomyelitis and retinitis, other associated paraneoplastic syndromes occurring with PON include cerebellar ataxia [<a href="#rid42">42,46,48-50</a>], a Devic-like syndrome [<a href="#rid42">42,43</a>], and ophthalmoplegia [<a href="#rid40">40,51</a>]. Optic nerve dysfunction can precede, accompany, or occur after other neurologic symptoms. Some patients have PON as the only neurologic manifestation [<a href="#rid42">42,47,52-55</a>].</p><p>PON usually occurs in the setting of known cancer, but occasionally is its first manifestation [<a href="#rid4">4</a>]. SCLC is the most commonly associated cancer, but PON along with anti-CRMP5 antibodies has been described in non-small cell lung cancer [<a href="#rid54">54,55</a>], breast cancer [<a href="#rid52">52</a>], thymoma [<a href="#rid43">43</a>], renal cancer [<a href="#rid42">42</a>], and thyroid cancer [<a href="#rid42">42</a>].</p><p>Vision may improve with antitumor treatment [<a href="#rid4">4,21,46</a>]. In some reports, systemic corticosteroids are also associated with improvement, but this is not invariable; associated neurologic symptoms appear less likely to respond to treatment [<a href="#rid21">21,44,53,54</a>]. One report describes visual improvement in two cases with intravitreal <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H4052000"><span class="h1">BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION</span><span class="headingEndMark"> — </span>Bilateral diffuse uveal melanocytic proliferation (BDUMP) describes a syndrome in which vision loss occurs along with diffuse bilateral proliferation of melanocytes in the uveal tract in patients with cancer. The mechanism is unknown, but does not appear to be mediated by autoimmunity.</p><p>Patients present with vision loss of varying severity [<a href="#rid56">56-59</a>]. Visual symptoms often precede cancer diagnosis; associated malignancies include ovarian, uterine, lung, and pancreatic cancers. Funduscopic examination is often normal at first presentation, but later may reveal multiple, subtle, round or oval, red patches. <a class="drug drug_general" data-topicid="8461" href="/d/drug information/8461.html" rel="external">Fluorescein</a> angiography reveals multifocal hyperfluorescence corresponding with these patches. Diffuse thickening of the uveal tract with elevated focal melanocytic tumors may also be seen. Optical coherence tomography reveals loss of the retinal pigment epithelium [<a href="#rid60">60-62</a>].</p><p>Bilateral retinal detachments and rapid cataract formation follow. Patients with BDUMP respond poorly if at all to surgical therapy, and most patients become blind. In limited reports, corticosteroid treatment does not appear to impact outcome [<a href="#rid58">58,63</a>]. Some patients with BDUMP treated with irradiation for presumed choroidal metastases have developed a decline in vision, but it is not clear whether progression was due to the disease process or a side effect from radiation [<a href="#rid2">2</a>]. However, one case report describes improved vision in a woman treated with external beam irradiation supplemented by drainage of subretinal fluid [<a href="#rid59">59</a>].</p><p>A serum-bound protein that stimulates melanocytic proliferation in vitro (melanocyte elongation and proliferation [CMEP] factor) was found in two patients with BDUMP [<a href="#rid64">64</a>]. Based on this finding, two patients were treated with plasmapheresis [<a href="#rid65">65</a>]. One patient had CMEP factor prior to treatment, and the other was not tested. Both patients responded with stabilization of visual function. One patient responded to intravitreal steroid implants [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H1636527261"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117968.html" rel="external">"Society guideline links: Paraneoplastic neurologic disorders"</a>.)</p><p class="headingAnchor" id="H2791288"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of syndromes</strong> – Paraneoplastic visual syndromes include cancer-associated retinopathy (CAR), melanoma-associated retinopathy (MAR), paraneoplastic optic neuropathy (PON), and bilateral diffuse uveal melanocytic proliferation (BDUMP). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Retinopathies</strong> – Immune-mediated damage to the retina occurs in two cancer-associated syndromes associated with a range of autoantibodies and underlying tumors.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cancer-associated retinopathy</strong> – Patients with CAR develop photosensitivity, abnormal visual acuity, color vision abnormalities, central or ring-like scotomata, and photopsias. Small cell lung cancer (SCLC) and gynecologic tumors are the most commonly associated tumors. (See <a class="local">'Cancer-associated retinopathy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Melanoma-associated retinopathy</strong> – Clinical features of MAR include shimmering, flickering, or pulsating photopsias, night blindness, and loss of peripheral vision. MAR may precede the diagnosis of melanoma. (See <a class="local">'Melanoma-associated retinopathy'</a> above.)</p><p></p><p class="bulletIndent1">Treatment of CAR and MAR is usually ineffective; however, some patients improve with treatment of the tumor or immunotherapy. (See <a class="local">'Cancer-associated retinopathy'</a> above and <a class="local">'Melanoma-associated retinopathy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paraneoplastic optic neuropathy</strong> – PON has been described in a few reports, usually in association with paraneoplastic encephalomyelitis or retinitis and SCLC. (See <a class="local">'Optic neuropathy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uveal melanocytic proliferation</strong> – BDUMP describes a rare paraneoplastic syndrome. Visual prognosis is poor because of bilateral retinal detachment and rapid cataract formation. Survival is shortened as well, with death resulting from complications of the underlying malignancy. (See <a class="local">'Bilateral diffuse uveal melanocytic proliferation'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ohguro H, Nakazawa M. Pathological roles of recoverin in cancer-associated retinopathy. Adv Exp Med Biol 2002; 514:109.</a></li><li><a class="nounderline abstract_t">Ko MW, Dalmau J, Galetta SL. Neuro-ophthalmologic manifestations of paraneoplastic syndromes. J Neuroophthalmol 2008; 28:58.</a></li><li><a class="nounderline abstract_t">Jacobson DM, Thirkill CE, Tipping SJ. A clinical triad to diagnose paraneoplastic retinopathy. Ann Neurol 1990; 28:162.</a></li><li><a class="nounderline abstract_t">Chan JW. Paraneoplastic retinopathies and optic neuropathies. Surv Ophthalmol 2003; 48:12.</a></li><li><a class="nounderline abstract_t">Adamus G. Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy. Autoimmun Rev 2009; 8:410.</a></li><li><a class="nounderline abstract_t">Jacobson DM, Adamus G. Retinal anti-bipolar cell antibodies in a patient with paraneoplastic retinopathy and colon carcinoma. Am J Ophthalmol 2001; 131:806.</a></li><li><a class="nounderline abstract_t">Katsuta H, Okada M, Nakauchi T, et al. Cancer-associated retinopathy associated with invasive thymoma. Am J Ophthalmol 2002; 134:383.</a></li><li><a class="nounderline abstract_t">Yamada G, Ohguro H, Aketa K, et al. Invasive thymoma with paraneoplastic retinopathy. Hum Pathol 2003; 34:717.</a></li><li><a class="nounderline abstract_t">Espandar L, O'Brien S, Thirkill C, et al. Successful treatment of cancer-associated retinopathy with alemtuzumab. J Neurooncol 2007; 83:295.</a></li><li><a class="nounderline abstract_t">Chang PY, Yang CH, Yang CM. Cancer-associated retinopathy in a patient with hepatocellular carcinoma: case report and literature review. Retina 2005; 25:1093.</a></li><li><a class="nounderline abstract_t">Adamus G, Ren G, Weleber RG. Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. BMC Ophthalmol 2004; 4:5.</a></li><li><a class="nounderline abstract_t">Eichen JG, Dalmau J, Demopoulos A, et al. The photoreceptor cell-specific nuclear receptor is an autoantigen of paraneoplastic retinopathy. J Neuroophthalmol 2001; 21:168.</a></li><li><a class="nounderline abstract_t">Shiraga S, Adamus G. Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway. J Neuroimmunol 2002; 132:72.</a></li><li><a class="nounderline abstract_t">Magrys A, Anekonda T, Ren G, Adamus G. The role of anti-alpha-enolase autoantibodies in pathogenicity of autoimmune-mediated retinopathy. J Clin Immunol 2007; 27:181.</a></li><li><a class="nounderline abstract_t">Ohguro H, Yokoi Y, Ohguro I, et al. Clinical and immunologic aspects of cancer-associated retinopathy. Am J Ophthalmol 2004; 137:1117.</a></li><li><a class="nounderline abstract_t">Keltner JL, Thirkill CE, Tyler NK, Roth AM. Management and monitoring of cancer-associated retinopathy. Arch Ophthalmol 1992; 110:48.</a></li><li><a class="nounderline abstract_t">Ferreyra HA, Jayasundera T, Khan NW, et al. Management of autoimmune retinopathies with immunosuppression. Arch Ophthalmol 2009; 127:390.</a></li><li><a class="nounderline abstract_t">Guy J, Aptsiauri N. Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol 1999; 117:471.</a></li><li><a class="nounderline abstract_t">Murphy MA, Thirkill CE, Hart WM Jr. Paraneoplastic retinopathy: a novel autoantibody reaction associated with small-cell lung carcinoma. J Neuroophthalmol 1997; 17:77.</a></li><li><a class="nounderline abstract_t">Mahdi N, Faia LJ, Goodwin J, et al. A case of autoimmune retinopathy associated with thyroid carcinoma. Ocul Immunol Inflamm 2010; 18:322.</a></li><li><a class="nounderline abstract_t">Damek DM. Paraneoplastic Retinopathy/Optic Neuropathy. Curr Treat Options Neurol 2005; 7:57.</a></li><li><a class="nounderline abstract_t">Ghoraba H, Or C, Karaca I, et al. Immunotherapy-induced retinopathy mimicking cancer associated retinopathy. Am J Ophthalmol Case Rep 2022; 26:101449.</a></li><li><a class="nounderline abstract_t">Audemard A, de Raucourt S, Miocque S, et al. Melanoma-associated retinopathy treated with ipilimumab therapy. Dermatology 2013; 227:146.</a></li><li><a class="nounderline abstract_t">Yeh OL, Francis CE. Ipilimumab-associated bilateral optic neuropathy. J Neuroophthalmol 2015; 35:144.</a></li><li><a class="nounderline abstract_t">Keltner JL, Thirkill CE, Yip PT. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol 2001; 21:173.</a></li><li><a class="nounderline abstract_t">Boeck K, Hofmann S, Klopfer M, et al. Melanoma-associated paraneoplastic retinopathy: case report and review of the literature. Br J Dermatol 1997; 137:457.</a></li><li><a class="nounderline abstract_t">Lu Y, Jia L, He S, et al. Melanoma-associated retinopathy: a paraneoplastic autoimmune complication. Arch Ophthalmol 2009; 127:1572.</a></li><li><a class="nounderline abstract_t">Berson EL, Lessell S. Paraneoplastic night blindness with malignant melanoma. Am J Ophthalmol 1988; 106:307.</a></li><li><a class="nounderline abstract_t">Milam AH, Saari JC, Jacobson SG, et al. Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. Invest Ophthalmol Vis Sci 1993; 34:91.</a></li><li><a class="nounderline abstract_t">Potter MJ, Adamus G, Szabo SM, et al. Autoantibodies to transducin in a patient with melanoma-associated retinopathy. Am J Ophthalmol 2002; 134:128.</a></li><li><a class="nounderline abstract_t">Bazhin AV, Dalke C, Willner N, et al. Cancer-retina antigens as potential paraneoplastic antigens in melanoma-associated retinopathy. Int J Cancer 2009; 124:140.</a></li><li><a class="nounderline abstract_t">Hartmann TB, Bazhin AV, Schadendorf D, Eichmüller SB. SEREX identification of new tumor antigens linked to melanoma-associated retinopathy. Int J Cancer 2005; 114:88.</a></li><li><a class="nounderline abstract_t">Pföhler C, Preuss KD, Tilgen W, et al. Mitofilin and titin as target antigens in melanoma-associated retinopathy. Int J Cancer 2007; 120:788.</a></li><li><a class="nounderline abstract_t">Dhingra A, Fina ME, Neinstein A, et al. Autoantibodies in melanoma-associated retinopathy target TRPM1 cation channels of retinal ON bipolar cells. J Neurosci 2011; 31:3962.</a></li><li><a class="nounderline abstract_t">Xiong WH, Duvoisin RM, Adamus G, et al. Serum TRPM1 autoantibodies from melanoma associated retinopathy patients enter retinal on-bipolar cells and attenuate the electroretinogram in mice. PLoS One 2013; 8:e69506.</a></li><li><a class="nounderline abstract_t">Ladewig G, Reinhold U, Thirkill CE, et al. Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV. Br J Dermatol 2005; 152:931.</a></li><li><a class="nounderline abstract_t">Shimazaki K, Jirawuthiworavong GV, Heckenlively JR, Gordon LK. Frequency of anti-retinal antibodies in normal human serum. J Neuroophthalmol 2008; 28:5.</a></li><li><a class="nounderline abstract_t">Subhadra C, Dudek AZ, Rath PP, Lee MS. Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin. J Neuroophthalmol 2008; 28:23.</a></li><li><a class="nounderline abstract_t">Jacobzone C, Cochard-Marianowski C, Kupfer I, et al. Corticosteroid treatment for melanoma-associated retinopathy: effect on visual acuity and electrophysiologic findings. Arch Dermatol 2004; 140:1258.</a></li><li><a class="nounderline abstract_t">Pillay N, Gilbert JJ, Ebers GC, Brown JD. Internuclear ophthalmoplegia and "optic neuritis": paraneoplastic effects of bronchial carcinoma. Neurology 1984; 34:788.</a></li><li><a class="nounderline abstract_t">Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49:146.</a></li><li><a class="nounderline abstract_t">Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003; 54:38.</a></li><li><a class="nounderline abstract_t">Ducray F, Roos-Weil R, Garcia PY, et al. Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2007; 78:325.</a></li><li><a class="nounderline abstract_t">Moss HE, Liu GT, Dalmau J. Glazed (vision) and confused. Surv Ophthalmol 2010; 55:169.</a></li><li><a class="nounderline abstract_t">Cohen DA, Bhatti MT, Pulido JS, et al. Collapsin Response-Mediator Protein 5-Associated Retinitis, Vitritis, and Optic Disc Edema. Ophthalmology 2020; 127:221.</a></li><li><a class="nounderline abstract_t">de la Sayette V, Bertran F, Honnorat J, et al. Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol 1998; 55:405.</a></li><li><a class="nounderline abstract_t">Sheorajpanday R, Slabbynck H, Van De Sompel W, et al. Small cell lung carcinoma presenting as collapsin response-mediating protein (CRMP) -5 paraneoplastic optic neuropathy. J Neuroophthalmol 2006; 26:168.</a></li><li><a class="nounderline abstract_t">Thambisetty MR, Scherzer CR, Yu Z, et al. Paraneoplastic optic neuropathy and cerebellar ataxia with small cell carcinoma of the lung. J Neuroophthalmol 2001; 21:164.</a></li><li><a class="nounderline abstract_t">Malik S, Furlan AJ, Sweeney PJ, et al. Optic neuropathy: a rare paraneoplastic syndrome. J Clin Neuroophthalmol 1992; 12:137.</a></li><li><a class="nounderline abstract_t">Luiz JE, Lee AG, Keltner JL, et al. Paraneoplastic optic neuropathy and autoantibody production in small-cell carcinoma of the lung. J Neuroophthalmol 1998; 18:178.</a></li><li><a class="nounderline abstract_t">Boghen D, Sebag M, Michaud J. Paraneoplastic optic neuritis and encephalomyelitis. Report of a case. Arch Neurol 1988; 45:353.</a></li><li><a class="nounderline abstract_t">Pulido J, Cross SA, Lennon VA, et al. Bilateral autoimmune optic neuritis and vitreitis related to CRMP-5-IgG: intravitreal triamcinolone acetonide therapy of four eyes. Eye (Lond) 2008; 22:1191.</a></li><li><a class="nounderline abstract_t">Arés-Luque A, García-Tuñón LA, Saiz A, et al. Isolated paraneoplastic optic neuropathy associated with small-cell lung cancer and anti-CV2 antibodies. J Neurol 2007; 254:1131.</a></li><li><a class="nounderline abstract_t">Murakami Y, Yoshida S, Yoshikawa H, et al. CRMP-5-IgG in patient with paraneoplastic optic neuritis with lung adenocarcinoma. Eye (Lond) 2007; 21:860.</a></li><li><a class="nounderline abstract_t">Asproudis IC, Nikas AN, Psilas KG. Paraneoplastic optic neuropathy in a patient with a non-small cell lung carcinoma: a case report. Eur J Ophthalmol 2005; 15:420.</a></li><li><a class="nounderline abstract_t">O'Neal KD, Butnor KJ, Perkinson KR, Proia AD. Bilateral diffuse uveal melanocytic proliferation associated with pancreatic carcinoma: a case report and literature review of this paraneoplastic syndrome. Surv Ophthalmol 2003; 48:613.</a></li><li><a class="nounderline abstract_t">Duong HV, McLean IW, Beahm DE. Bilateral diffuse melanocytic proliferation associated with ovarian carcinoma and metastatic malignant amelanotic melanoma. Am J Ophthalmol 2006; 142:693.</a></li><li><a class="nounderline abstract_t">Saito W, Kase S, Yoshida K, et al. Bilateral diffuse uveal melanocytic proliferation in a patient with cancer-associated retinopathy. Am J Ophthalmol 2005; 140:942.</a></li><li><a class="nounderline abstract_t">Ritland JS, Eide N, Tausjø J. Bilateral diffuse uveal melanocytic proliferation and uterine cancer. A case report. Acta Ophthalmol Scand 2000; 78:366.</a></li><li><a class="nounderline abstract_t">Kiratli H, Erkan K. Loss of Retinal Pigment Epithelium Associated with Bilateral Diffuse Uveal Melanocytic Proliferation. Ophthalmic Surg Lasers Imaging 2010; :1.</a></li><li><a class="nounderline abstract_t">Besirli CG, Comer GM. High-resolution OCT imaging of RPE degeneration in bilateral diffuse uveal melanocytic proliferation. Ophthalmic Surg Lasers Imaging 2010; 41 Suppl:S96.</a></li><li><a class="nounderline abstract_t">Wu S, Slakter JS, Shields JA, Spaide RF. Cancer-associated nummular loss of the pigment epithelium. Am J Ophthalmol 2005; 139:933.</a></li><li><a class="nounderline abstract_t">Sen J, Clewes AR, Quah SA, et al. Presymptomatic diagnosis of bronchogenic carcinoma associated with bilateral diffuse uveal melanocytic proliferation. Clin Exp Ophthalmol 2006; 34:156.</a></li><li><a class="nounderline abstract_t">Miles SL, Niles RM, Pittock S, et al. A factor found in the IgG fraction of serum of patients with paraneoplastic bilateral diffuse uveal melanocytic proliferation causes proliferation of cultured human melanocytes. Retina 2012; 32:1959.</a></li><li><a class="nounderline abstract_t">Jansen JC, Van Calster J, Pulido JS, et al. Early diagnosis and successful treatment of paraneoplastic melanocytic proliferation. Br J Ophthalmol 2015; 99:943.</a></li><li><a class="nounderline abstract_t">Gemperline TP, Smith BT. TREATMENT OF BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION WITH INTRAVITREAL STEROID IMPLANTS. Retin Cases Brief Rep 2022; 16:461.</a></li></ol></div><div id="topicVersionRevision">Topic 15837 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12596918" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pathological roles of recoverin in cancer-associated retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18347462" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Neuro-ophthalmologic manifestations of paraneoplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2171418" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A clinical triad to diagnose paraneoplastic retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12559325" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Paraneoplastic retinopathies and optic neuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19168157" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Autoantibody targets and their cancer relationship in the pathogenicity of paraneoplastic retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11384586" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Retinal anti-bipolar cell antibodies in a patient with paraneoplastic retinopathy and colon carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12208250" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cancer-associated retinopathy associated with invasive thymoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12874770" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Invasive thymoma with paraneoplastic retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17252185" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Successful treatment of cancer-associated retinopathy with alemtuzumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16340542" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cancer-associated retinopathy in a patient with hepatocellular carcinoma: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15180904" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11725181" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The photoreceptor cell-specific nuclear receptor is an autoantigen of paraneoplastic retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12417436" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17235687" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The role of anti-alpha-enolase autoantibodies in pathogenicity of autoimmune-mediated retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15183799" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical and immunologic aspects of cancer-associated retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1310001" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Management and monitoring of cancer-associated retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19365013" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Management of autoimmune retinopathies with immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10206574" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9176775" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Paraneoplastic retinopathy: a novel autoantibody reaction associated with small-cell lung carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20662664" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A case of autoimmune retinopathy associated with thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15610708" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Paraneoplastic Retinopathy/Optic Neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35265774" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Immunotherapy-induced retinopathy mimicking cancer associated retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24051549" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Melanoma-associated retinopathy treated with ipilimumab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25647225" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ipilimumab-associated bilateral optic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11725182" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9349350" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Melanoma-associated paraneoplastic retinopathy: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20008709" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Melanoma-associated retinopathy: a paraneoplastic autoimmune complication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2971322" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Paraneoplastic night blindness with malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8425845" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12095824" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Autoantibodies to transducin in a patient with melanoma-associated retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18814277" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cancer-retina antigens as potential paraneoplastic antigens in melanoma-associated retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15523688" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : SEREX identification of new tumor antigens linked to melanoma-associated retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17131336" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mitofilin and titin as target antigens in melanoma-associated retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21411639" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Autoantibodies in melanoma-associated retinopathy target TRPM1 cation channels of retinal ON bipolar cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23936334" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Serum TRPM1 autoantibodies from melanoma associated retinopathy patients enter retinal on-bipolar cells and attenuate the electroretinogram in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888149" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18347451" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Frequency of anti-retinal antibodies in normal human serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18347454" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15492190" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Corticosteroid treatment for melanoma-associated retinopathy: effect on visual acuity and electrophysiologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6539443" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Internuclear ophthalmoplegia and "optic neuritis": paraneoplastic effects of bronchial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11220734" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12838519" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17308295" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19804892" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Glazed (vision) and confused.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31676123" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Collapsin Response-Mediator Protein 5-Associated Retinitis, Vitritis, and Optic Disc Edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9520015" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16966932" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Small cell lung carcinoma presenting as collapsin response-mediating protein (CRMP) -5 paraneoplastic optic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11725180" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Paraneoplastic optic neuropathy and cerebellar ataxia with small cell carcinoma of the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1328306" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Optic neuropathy: a rare paraneoplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9736201" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Paraneoplastic optic neuropathy and autoantibody production in small-cell carcinoma of the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3341961" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Paraneoplastic optic neuritis and encephalomyelitis. Report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17721501" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Bilateral autoimmune optic neuritis and vitreitis related to CRMP-5-IgG: intravitreal triamcinolone acetonide therapy of four eyes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17401741" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Isolated paraneoplastic optic neuropathy associated with small-cell lung cancer and anti-CV2 antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17277748" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : CRMP-5-IgG in patient with paraneoplastic optic neuritis with lung adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15945016" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Paraneoplastic optic neuropathy in a patient with a non-small cell lung carcinoma: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14609707" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Bilateral diffuse uveal melanocytic proliferation associated with pancreatic carcinoma: a case report and literature review of this paraneoplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17011873" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Bilateral diffuse melanocytic proliferation associated with ovarian carcinoma and metastatic malignant amelanotic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16310487" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Bilateral diffuse uveal melanocytic proliferation in a patient with cancer-associated retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893075" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Bilateral diffuse uveal melanocytic proliferation and uterine cancer. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20438043" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Loss of Retinal Pigment Epithelium Associated with Bilateral Diffuse Uveal Melanocytic Proliferation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21117612" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : High-resolution OCT imaging of RPE degeneration in bilateral diffuse uveal melanocytic proliferation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15860313" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cancer-associated nummular loss of the pigment epithelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16626431" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Presymptomatic diagnosis of bronchogenic carcinoma associated with bilateral diffuse uveal melanocytic proliferation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22791177" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A factor found in the IgG fraction of serum of patients with paraneoplastic bilateral diffuse uveal melanocytic proliferation causes proliferation of cultured human melanocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25908835" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Early diagnosis and successful treatment of paraneoplastic melanocytic proliferation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32649362" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : TREATMENT OF BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION WITH INTRAVITREAL STEROID IMPLANTS.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
